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Abstract: The synthesis and antiproliferative activity of new benzimidazole derivatives bearing an
hydrazone mojety at the 2-position is described. The new N1-(4-arylidene)-1H-benzo[d]imidazole-2-
carbohydrazides were evaluated for their cytostatic activity toward the murine leukemia (L1210),
human T-cell leukemia (CEM), human cervix carcinoma (HeLa) and human pancreas carcinoma
cells (Mia Paca-2). A preliminary structure-activity relationship could be defined. Some of the
compounds possess encouraging and consistent antiproliferative activity, having IC50 values in the
low micromolar range.
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1. Introduction
As recently reviewed [1], benzimidazole is a privileged structure in medicinal chemistry because
of its broad range of biological activities. The benzimidazole ring is present in some clinically used
drugs, such as proton pump inhibitors, antihelmintic compounds, the antiviral enviroxime and the
antihistaminic astemizole, but it may also display antimycobacterial, antimicrobial, anticonvulsant,
analgesic, anti-inflammatory, anti-diabetic, antiprotozoal, antipsychotic, antioxidant and antitumoral
properties [1].
Several series of benzimidazole derivatives have shown antiproliferative activity. Moreover,
benzimidazole-5-carboxylic acid derivatives induced cell death in leukemic cells [2]. The antiproliferative
activity of benzimidazole derivatives has been correlated to multi-target kinase inhibition [3,4].
Furthermore, benzimidazole carbamates showed antitubulin activity [5,6] and benzimidazole-
carbazole conjugates were described to stabilize human telomeric DNA and to inhibit telomerase and
topoisomerase I in cancer cells [7,8]. Benzimidazole has also been reported as a new scaffold endowed
with sirtuin 1 and 2 inhibitory activity. These compounds also showed cytotoxicity against the breast
cancer cell lines MCF-7 and MDA-MB-468 [9,10].
Hydrazone is another biologically active pharmacophore group. N-(11-Naphthyl)-3,4,5-
trimethoxybenzohydrazide has been reported as a potential anti-leukemia agent acting as a
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microtubule destabilizer [11]. 2-N-Heteroaryl caffeine hydrazones demonstrated high activity toward
T-lymphoblastic leukemia cells and inhibited both RNA and DNA synthesis and mitosis [12].
4-(2-Fluorophenoxy)quinolineacylhydrazones showed excellent antiproliferative activity and c-Met
kinase inhibitory activity [13]. Salicylaldehyde isonicotinoylhydrazone analogs behaved as iron
chelators especially in MCF-7 breast adenocarcinoma cells and this was correlated to their
cytotoxic activity [14], while salicylaldehyde 1-arylmethyl-3-aryl-1H-pyrazole-5-carbohydrazide
hydrazone derivatives inhibited the growth of A549 lung cancer cells [15]. We have previously
reported on 2-arylamino-6-trifluoromethyl-3-(hydrazinocarbonyl)pyridines [16] showing in vitro
inhibitory activity against human tumour cell lines at low micromolar to nanomolar concentrations.
Furthermore 4-(diethylamino)salycilaldehyde hydrazones showed potent cytotoxicity against human
tumour cell lines but showed no toxicity in athymic nude mice [17]. Although the biological
activity of benzimidazole and hydrazine structures has been well documented, an extensive
literature search revealed very few efforts to combine these two important moieties in a single
molecular scaffold. Few studies described the anti-inflammatory and antimicrobial activity of
benzimidazole-5-carboxylate and its hydrazone derivatives [18] and the antiproliferative activity
of N-1-benzoimidazole acetohydrazides against various tumor cell lines [19]. Therefore, in this
explorative work, based on the antiproliferative activity of benzimidazole and hydrazone containing
structures we decided to investigate, in a dualistic approach [20], new benzimidazole-hydrazone




The target hydrazones 3–19 were synthesized as shown in Scheme 1. High yields of
1H-benzo[d]imidazole-2-carbohydrazide (2) were achieved upon refluxing for 3 h in an ethanolic
solution of the corresponding ethyl ester 1 and hydrazine hydrate. Hydrazones 3–19 were obtained
in good to excellent yield by coupling the hydrazide 2 with the appropriate hydroxyarylaldehydes
in ethanol. All the newly synthesized compounds gave corrected analytical data. The IR and NMR
spectral data are consistent with the assigned structure. According to the literature, the presence
of a single downfield resonating (8.49–9.79 ppm) CH=N signal indicates the exclusive formation of
E-isomers [21].
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Scheme 1. Synthesis of hydrazones 3–19. Reagents and conditions: (i) NH2NH2·H2O, EtOH, reflux, 3 h; 
(ii) ArCHO, EtOH reflux, 5 h. 
2.2. Antiproliferative Activity 
The synthesized hydrazones 3–19 were evaluated in vitro for their inhibitory effects on the 
proliferation of murine leukemia (L1210), human T-lymphoblastic leukemia (CEM), human cervix 
carcinoma (HeLa) and human pancreas carcinoma (Mia Paca-2) cells. The presence of a 2-hydroxyl 
group on the arylidene moiety favourably modulates antiproliferative activity (Table 1). 
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2.2. Antiproliferative Activity
The synthesized hydrazones 3–19 were evaluated in vitro for their inhibitory effects on the
proliferation of murine leukemia (L1210), human T-lymphoblastic leukemia (CEM), human cervix
carcinoma (HeLa) and human pancreas carcinoma (Mia Paca-2) cells. The presence of a 2-hydroxyl
group on the arylidene moiety favourably modulates antiproliferative activity (Table 1).
Table 1. Antiproliferative activity of N1-(4-arylidene)-1H-benzo[d]imidazole-2-carbohydrazides 3–19.
Compd. Ar IC50 (µM) a
L1210 CEM HeLa Mia-Paca-2
3 2-OH-phenyl 5.7 ˘ 0.9 4.4 ˘ 0.2 12 ˘ 0.7 34 ˘ 0.9
4 3-OH-phenyl 94 ˘ 7 98 ˘ 10 88 ˘ 12.5 >100
5 4-OH-phenyl 47 ˘ 2 85 ˘ 0.01 >100 >100
6 2,4-(OH)2-phenyl 2.6 ˘ 0.9 2.6 ˘ 1.0 4.7 ˘ 1.6 21 ˘ 12
7 2,5-(OH)2-phenyl 22 ˘ 7 4.9 ˘ 1.2 77 ˘ 18 >100
8 2,3,4-(OH)3-phenyl 47 ˘ 7 20 ˘ 8 97 ˘ 28 >100
9 2,4,6-(OH)3-phenyl 90 ˘ 7 >100 >100 >100
10 2-OH-4-OMe-phenyl 1.6 ˘ 0.9 0.98 ˘ 0.02 4.0 ˘ 0.4 6.3 ˘ 3.2
11 2-OH-3-OEt-phenyl 5.9 ˘ 2.4 6.3 ˘ 1.9 22 ˘ 0.02 23 ˘ 8
12 3-OH-4-OMe-phenyl 92 ˘ 4 57 ˘ 3.7 >100 >100
13 2-OH-4-N(Et)2-phenyl 14 ˘ 2 4.8 ˘ 0.8 23 ˘ 3 40 ˘ 6
14 2-OH-5-Cl-phenyl 7.4 ˘ 2.5 1.8 ˘ 0.6 4.8 ˘ 0.9 9.2 ˘ 4.0
15 2-OH-5-Br-phenyl 5.0 ˘ 2.8 1.8 ˘ 0.9 4.9 ˘ 0.4 35 ˘ 5
16 2-OH-naphtyl 2.9 ˘ 1.3 1.0 ˘ 0.01 2.5 ˘ 1.4 7.9 ˘ 0.3
17 phenyl >250 >250 >250 220 ˘ 37
18 4-OMe-phenyl >250 >250 >250 >250
19 napht-1-yl 240˘13 >250 >250 >250
a IC50 values (compound concentration that reduces cell growth by 50%) are shown.
3. Discussion
Hydrazones 10 and 16 inhibited the growth of all tested cell lines with low (<10 µM)
micromolar IC50 values. The replacement of the 2-hydroxynaphthyl group of compound 16 with the
2-hydroxyphenyl resulted in the hydrazone 3 endowed with reduced antiproliferative activity against
HeLa and Mia Paca-2 cells. The shift of the hydroxyl group from the 2-position to the 3- or 4-position
led to poorly active compounds 4 and 5. The introduction of a second 4-hydroxyl group (compound 6)
caused an increase in activity with respect to the 2-hydroxy analog 3, whereas the presence of the
2,5-dihydroxybenzylidene group (compound 7) led to a clear reduction in inhibitory activity as
compared with compounds 4 and 6. The introduction of a third hydroxyl group (compounds 8 and 9)
resulted in reduction or loss of cytostatic activity. A comparison of substituent effects revealed that the
introduction of a 2-hydroxy-5-halobenzylidene moiety led to compounds 14 and 15 endowed with a
better antiproliferative effect as compared with 2,5-dihydroxybenzylidene and 2-hydroxybenzylidene
analogs 7 and 4. The hydrazone of 5-chlorosalicylaldehyde 14 showed antiproliferative activity at
single digit micromolar IC50 values on all tumor cell lines, while the 5-bromo derivative 15 was
less active on Mia Paca-2 cells. The introduction of the 2-hydroxy-4-methoxybenzylidene moiety
(compound 10) caused an increase in activity as compared with 2,4-dihydroxybenzylidene and
2-hydroxybenzylidene analogs 6 and 3. A reduction in activity was produced by the shift of the
ether group from the 4- to the 3-position (hydrazone 11), while the shift of the hydroxyl group from the
2- to the 3-position (compound 12) led to a drop in activity. The replacement of the 4-methoxy group
with a 4-(diethylamino) group was tolerated although hydrazone 13 was less active as compared with
hydrazones 3 and 6. The hydrazones 17–19 lacking hydroxyl groups are completely inactive.
The efficacy of any drug depends on its high oral bioavailability, so we assessed the potential
bioavailability of the most active compounds, using the adsorption, distribution, metabolism
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and elimination (ADME) prediction method by molinspiration (http://www.molinspiration.com/
cgi-bin/properties).
According to Lipinski’s rule of five [22] a compound to become a successful drug candidate,
should have a molecular weight ď500, a log p ď 5, hydrogen bond donor sites ď5 and hydrogen bond
acceptor sites (N and O atoms) ď10. Predictions of the ADME properties for studied compounds
(Table 2) showed that all the active compounds fulfilled this rule, similarly to clinically used drugs.
Furthermore, the number of rotable bonds is important for conformational flexibility of the molecule.
The total polar surface area (TPSA) is another key property that has been linked to drug bioavailability.
These two parameters, i.e., the number of rotable bonds in a molecule ď10 and polar surface area
ď140 Å are essential for a good oral bioavailability [23]. Theoretically, all hydrazones 3, 6–8, 10,
11, 13–16 should present good passive oral absorption and differences in their bioactivity cannot be
attributed to this property.
Table 2. In silico physico-chemical properties (ADME) of active compounds 3, 6–8, 10, 11, 13–16.
Compd. TPSA n-ROTB MV MW miLogP n-ON n-OHNH n-Viol
3 90.37 3 242.94 280.29 2.64 6 3 0
6 110.60 3 250.96 296.29 2.13 7 4 0
7 110.60 3 250.96 296.29 2.13 7 4 0
8 130.83 3 258.97 312.29 1.67 8 5 0
10 99.61 4 268.48 310.31 2.677 7 3 0
11 99.61 5 285.29 324.34 2.62 7 3 0
13 93.61 6 322.45 351.41 3.47 7 3 0
14 90.37 3 256.47 314.73 3.29 6 3 0
15 90.37 3 260.82 359.18 3.42 6 3 0
16 90.37 3 286.93 330.35 3.79 6 3 0
TPSA: topological polar surface area; n-ROTB: number of rotable bonds; MV: molecular volume; MW: molecular
weight; milogP: logarithm of partition coefficient between n-octanol and water; n-ON: number of hydrogen
bond acceptors; n-OHNH: number of hydrogen bond donors; n-Viol: number of violations of Lipinski’s rule.
4. Materials and Methods
4.1. General Information
All commercially available solvents and reagents were used without further purification. 1H- and
13C-NMR spectra were recorded on an Inova 500 spectrometer (Varian, Palo Alto, CA, USA).
The chemical shifts (δ) are reported in part per million downfield from tetramethylsilane (TMS), which
was used as internal standard, and the spectra were recorded in hexadeuteriodimethylsulphoxide
(DMSO-d6). Infrared spectra were recorded on a Vector 22 spectrometer (Bruker, Bremen, Germany) in
Nujol mulls. The main bands are given in cm´1. Positive-ion electrospray ionization (ESI) mass spectra
were recorded on a double-focusing MAT 95 instrument (Finnigan, Waltham, MA, USA) with BE
geometry. Melting points (mp) were determined on a SMP1 Melting Point apparatus (Stuart Scientific,
Stone, UK) and are uncorrected. All products reported showed 1H NMR spectra in agreement with the
assigned structures. The purity of the tested compounds was determined by combustion elemental
analyses conducted by the Microanalytical Laboratory of the Chemistry Department of the University
of Ferrara with a MT-5 CHN recorder elemental analyzer (Yanagimoto, Kyoto, Japan) and the values




A mixture of ethyl 1H-benzo[d]imidazole-2-carboxylate (1, 3.80 g, 20 mmol), and hydrazine
monohydrate (3 mL, 61.5 mmol) in EtOH (5 mL) was refluxed for 3 h. After cooling the formed
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precipitate was filtered off, washed with water (5ˆ 10 mL) dried and used without further purification.
Yield 80%. Mp 240–242 ˝C (lit. [25] 217–219). IR: 3321, 3265, 3066, 1661, 1609 cm´1. 1H-NMR: δ 4.62
(s, 2H, NH2), 7.28 (m, 2H, Ar), 7.53 (d, J = 8.0 Hz, 1H, Ar), 7.70 (d, J = 8.0 Hz, 1H, Ar), 10.14 (s, 1H, NH),
13.20 (s, 1H, NH). ESI-MS m/z 177 (M + H)+. Anal. Calcd for C8H8N4O: C, 54.54; H, 4.58; N, 31.80.
Found: C, 54.57; H, 4.57; N, 31.76.
4.2.1. General Procedure for the Synthesis of Hydrazones 3–19
A mixture of hydrazide 2 (1 mmol) and the appropriate aldehyde (1 mmol) in EtOH (10 mL) was
refluxed for 5 h. After cooling the formed precipitate was filtered off and purified by crystallization
from the adequate solvent to give the hydrazone derivatives.
(E)-N1-(2-Hydroxybenzylidene)-1H-benzo[d]imidazole-2-carbohydrazide (3). Yield 78%. Mp > 250 ˝C (EtOH).
IR: 3191, 1664, 1614, 1556 cm´1. 1H-NMR: δ 6.94 (m, 2H, Ar), 7.31 (m, 3H, Ar) 7.67 (m, 3H, Ar), 8.83
(s, 1H, CH), 11.23 (s, 1H, OH), 12.78 (s, 1H, NH), 13.51 (s, 1H, NH). 13C-NMR: δ 105.4, 109.9, 115.1,
115.9, 123.0, 126.8, 129.7, 136.3, 135.2, 138.4, 141.2, 145.9, 150.1. ESI-MS m/z 281 (M + H)+. Anal. Calcd
for C15H12N4O2: C, 64.28; H, 4.32; N, 19.99. Found: C, 64.22; H, 4.33; N, 20.05.
(E)-N1-(3-Hydroxybenzylidene)-1H-benzo[d]imidazole-2-carbohydrazide (4). Yield 78%. Mp > 250 ˝C (EtOH).
IR: 3221, 1677, 1610, 1576 cm´1. 1H-NMR: δ 6.85 (d, J = 8.0 Hz, 1H, Ar), 7.11 (d, J = 7.5 Hz, 1H, Ar),
7.21 (s, 1H, Ar), 7.26 (d, J = 7.5 Hz, 1H, Ar), 7.29–7.78 (m, 4H, Ar), 8.56 (s, 1H, CH), 9.69 (s, 1H, OH),
12.40 (s, 1H, NH), 13.47 (s, 1H, NH). 13C-NMR: δ 105.3, 105,4, 109.8, 117.1, 117.9, 123.1, 130.1, 129.8,
138.7, 138.8, 144.3, 149.9, 150.2. ESI-MS m/z 281 (M+ H)+. Anal. Calcd for C15H12N4O2: C, 64.28; H,
4.32; N, 19.99. Found: C, 64.34; H, 4.31; N, 20.03.
(E)-N1-(4-Hydroxybenzylidene)-1H-benzo[d]imidazole-2-carbohydrazide (5). Yield 80%. Mp > 250 ˝C
(1-PrOH). IR: 3289, 1668,1609, 1584 cm´1. 1H-NMR: δ 6.86 (d, J = 8.5 Hz, 2H, Ar), 7.34 (d, J = 7.0 Hz,
2H, Ar), 7.57–7.59 (m, 3H, Ar), 7.77 (d, J = 7.0 Hz, 1H, Ar), 8.53 (s, 1H, CH), 10.03 (s, 1H, OH), 12.23
(s, 1H, NH), 13.43 (s, 1H, NH). 13C-NMR: δ 105.8, 106,3, 116.8, 118.4, 130.3, 139.8, 144.8, 150.9, 152.3.
ESI-MS m/z 281 (M + H)+. Anal. Calcd for C15H12N4O2: C, 64.28; H, 4.32; N, 19.99. Found: C, 64.33;
H, 4.31; N, 20.04.
(E)-N1-(2,4-Dihydroxybenzylidene)-1H-benzo[d]imidazole-2-carbohydrazide (6). Yield 75%. Mp > 250 ˝C
(1-PrOH). IR: 3227, 1673, 1638, 1587 cm´1. 1H-NMR: δ 6.34 (m, 2H, Ar), 6.38 (d, J = 6.5 Hz, 1H, Ar), 7.57
(m, 4H, Ar), 8.68 (s, 1H, CH), 10.09 (s, 1H, OH), 11.43 (s, 1H, OH), 12.59 (s, 1H, NH), 13.45 (s, 1H, NH).
13C-NMR: δ 105.0, 109.6, 115.1, 115.9, 123.2, 125.9, 127.6, 134.7, 135.1, 137.8, 145.9, 148.0. ESI-MS m/z
297 (M + H)+. Anal. Calcd for C15H12N4O3: C, 60.81; H, 4.08; N, 18.91. Found: C, 60.76; H, 4.10;
N, 18.94.
(E)-N1-(2,5-Dihydroxybenzylidene)-1H-benzo[d]imidazole-2-carbohydrazide (7). Yield 81%. Mp > 250 ˝C
(EtOH). IR: 3238, 1681, 1620, 1586 cm´1. 1H-NMR: δ 6.77 (d, J = 9.0 Hz, 1H, Ar), 6.79 (d, J = 9.0 Hz,
1H, Ar), 6.96 (s, 1H, Ar), 7.59 (m, 4H, Ar), 8.75 (s, 1H, CH) 9.03 (s, 1H, OH), 10.38 (s, 1H, OH), 12.67
(s, 1H, NH), 13.48 (s, 1H, NH). 13C-NMR: δ 105.7, 110.3, 115.6, 116.0, 123.3, 126.5, 130.2, 134.9, 135.6,
138.1, 145.8, 148.1. ESI-MS m/z 297 (M + H)+. Anal. Calcd for C15H12N4O3: C, 60.81; H, 4.08; N, 18.91.
Found: C, 60.86; H, 4.09; N, 18.87.
(E)-N1-(2,3,4-Trihydroxybenzylidene)-1H-benzo[d]imidazole-2-carbohydrazide (8). Yield 62%. Mp > 250 ˝C
(EtOH). IR: 3228, 3127, 3061, 1672, 1644 cm´1. 1H-NMR: δ 6.42 (d, J = 8.5 Hz, 1H, Ar), 6.76 (d, J = 8.5 Hz,
1H, Ar), 7.64 (m, 4H, Ar), 8.65 (s, 1H, CH), 9.57 (s, 2H, OH), 11.49 (s, 1H, OH), 12.65 (s, 1H, NH), 13.48
(s, 1H, NH). 13C-NMR: δ 106.2, 111.0, 115.7, 116.1, 125.6, 127.1, 135.0, 138.6, 138.7, 139.9, 147.1, 149.2.
ESI-MS m/z 313 (M + H)+. Anal. Calcd for C15H12N4O4: C, 57.69; H, 3.87; N, 17.94. Found: C, 57.64;
H, 3.88; N, 17.91.
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(E)-N1-(2,4,6-Trihydroxybenzylidene)-1H-benzo[d]imidazole-2-carbohydrazide (9). Yield 60%. Mp > 250 ˝C
(EtOH). IR: 3225, 1672, 1592 cm´1. 1H-NMR: δ 5.80 (s, 1H, Ar) 5.86 (s, 1H, Ar), 7.26 (d, J = 7.0 Hz,
1H, Ar), 7.30–7.78 (m, 3H, Ar), 8.98 (s, 1H, CH), 10.14 (s, 1H, OH), 11.14 (s, 2H, OH), 12.68 (s, 1H, NH),
13.43 (s, 1H, NH). 13C-NMR: δ 99.2, 103.9, 119.7, 127.9, 138.9, 140.1, 145.2, 147.4, 151.0. ESI-MS m/z 313
(M + H)+. Anal. Calcd for C15H12N4O4: C, 57.69; H, 3.87; N, 17.94. Found: C, 57.73; H, 3.86; N, 17.92.
(E)-N1-(2-Hydroxy-4-methoxybenzylidene)-1H-benzo[d]imidazole-2-carbohydrazide (10). Yield 79%. Mp > 250 ˝C
(EtOH). IR: 3214, 1665, 1633, 1607, 1567 cm´1. 1H-NMR: δ 3.79 (s, 3H, OCH3), 6.54 (m, 2H, Ar), 7.48
(m, 5H, Ar), 8.74 (s, 1H, CH), 11.55 (s, 1H, NH), 12.69 (s, 1H, OH), 13.47 (s, 1H, NH). 13C-NMR: δ 58.5,
104.4, 109.7, 114.9, 115.8, 123.1, 126.0, 127.6, 134.5, 135.2, 137.7, 145.7, 147.6. δ ESI-MS m/z 311 (M + H)+.
Anal. Calcd for C16H14N4O3: C, 61.93; H, 4.55; N, 18.06. Found: C, 61.99; H, 4.53; N, 18.02.
(E)-N1-(3-Ethoxy-2-hydroxybenzylidene)-1H-benzo[d]imidazole-2-carbohydrazide (11). Yield 70%. Mp > 250 ˝C
(EtOH). IR: 3322, 1694, 1610, 1583 cm´1. 1H-NMR: δ 1.36 (t, J = 7.0 Hz, 3H, CH3), 4.07 (q, J = 7.0 Hz,
2H, CH2), 6.86 (m, 1H, Ar), 7.03 (d, J = 8.0 Hz, 1H, Ar), (d, J = 8.0 Hz, 1H, Ar), 7.59 (m, 4H, Ar), 8.84
(s, 1H, CH), 10.99 (s, 1H, NH), 12.81 (s, 1H, OH), 13.53 (s, 1H, NH). 13C-NMR: δ 14.9, 65.0, 106.3, 107.7,
115.6, 115.8, 123.1, 124.5, 129.9, 135.8, 137.9, 146.2, 147.4, 149.2. ESI-MS m/z 325 (M + H)+. Anal. Calcd
for C17H16N4O3: C, 62.95; H, 4.97; N, 17.27. Found: C, 63.01; H, 4.99; N, 17.23.
(E)-N1-(3-Hydroxy-4-methoxybenzylidene)-1H-benzo[d]imidazole-2-carbohydrazide (12). Yield 71%. Mp > 250 ˝C
(EtOH). IR: 3277, 3219, 1673, 1612, 1567 cm´1. 1H-NMR: δ 3.96 (s, 3H, OCH3), 6.99 (d, J = 8.5 Hz,
1H, Ar), 7.0 (d, J = 8.5 Hz, 1H, Ar), 7.29 (s, 1H, Ar), 7.49 (m, 4H, Ar), 8.49 (s, 1H, CH), 9.39 (br s, 1H,
OH), 12.25 (br s, 1H, NH), 13.20 (br s, 1H, NH). 13C-NMR: δ 58.5, 106.0, 106.3, 110.1, 115.9, 116.7, 124.8,
128.5, 129.7, 135.4, 136.1, 145.4, 146.9. ESI-MS m/z 311 (M + H)+. Anal. Calcd for C16H14N4O3: C, 61.93;
H, 4.55; N, 18.06. Found: C, 61.88; H, 4.56; N, 18.10.
(E)-N1-(4-(Diethylamino)-2-hydroxybenzylidene)-1H-benzo[d]imidazole-2-carbohydrazide (13). Yield 78%.
Mp > 250 ˝C (EtOH). IR: 1668, 1631, 1586 cm´1. 1H-NMR: δ 1.10 (t, J = 7.0 Hz, 6H, CH3), 3.35
(q, J = 7.0 Hz, 4H, CH2), 6.12 (s, 1H, Ar), 6.27 (d, J = 6.0 Hz, 1H, Ar), 7.14 (d, J = 6.0 Hz, 1H, Ar), 7.32
(m, 2H, Ar), 7.57(m, 1H, Ar), 7.77 (m, 1H, Ar), 8.60 (s, 1H, CH), 11.42 (s, 1H, OH), 12.52 (s, 1H, NH),
13.42 (s, 1H, NH). 13C-NMR: δ 13.2, 48.9, 99.2, 103.6, 106.7, 109.9, 115.9, 122.7, 125.9, 131.4, 137.7, 140.0,
142.3, 146.2, 150.6. ESI-MS m/z 352 (M + H)+. Anal. Calcd for C19H21N5O2: C, 64.94; H, 6.02; N, 19.93.
Found: C, 65.01; H, 5.99; N, 19.97.
(E)-N1-(5-Chloro-2-hydroxybenzylidene)-1H-benzo[d]imidazole-2-carbohydrazide (14). Yield 85%. Mp > 250 ˝C
(EtOH). IR: 3215, 1680, 1605, 1591 cm´1. 1H-NMR: δ 6.96 (d, J = 8.0 Hz, 1H, Ar), 7.33–7.65 (m, 6H, Ar),
8.82 (s, 1H, CH), 11.15 (br s, 1H, OH), 12.90 (br s, 1H, NH), 13.30 (br s, 1H, NH). 13C-NMR: δ 105.6,
107.4, 109.9, 115.9, 117.2, 122.8, 123.0, 128.0, 129.5, 134.4, 141.5, 141.9, 147.6, 151.2. ESI-MS m/z 315
(M + H)+. Anal. Calcd for C15H11ClN4O2: C, 57.24; H, 3.52; N, 17.80. Found: C, 57.30; H, 3.51; N, 17.83.
(E)-N1-(5-Bromo-2-hydroxybenzylidene)-1H-benzo[d]imidazole-2-carbohydrazide (15). Yield 82%. Mp > 250 ˝C
(EtOH). IR: 3200, 1680, 1602, 1588 cm´1. 1H-NMR: δ 6.91 (d, J = 9.0 Hz, 1H, Ar), 7.33 (d, J = 6.0 Hz,
1H, Ar), 7.35 (d, J = 6.0 Hz, 1H, Ar), 7.60 (m, 4H, Ar), 8.81 (s, 1H, CH), 11.15 (s, 1H, OH), 12.85 (s,1H,
NH), 13.50 (s, 1H, NH). 13C-NMR: δ 105.2, 107.5, 109.9, 116.0, 117.3, 122.9, 123.0, 128.2, 129.4, 134.5,
141.5, 142.0, 147.7, 151.1. ESI-MS m/z 359 (M + H)+. Anal. Calcd for C15H11BrN4O2: C, 50.16; H, 3.09;
N, 15.60. Found: C, 50.22; H, 3.11; N, 15.57.
(E)-N1-((2-Hydroxynaphthalen-1-yl)methylene)-1H-benzo[d]imidazole-2-carbohydrazide (16). Yield 85%.
Mp > 250 ˝C (EtOH). IR: 3254, 1679, 1625, 1576 cm´1. 1H-NMR: δ 7.26 (d, J = 9.0 Hz, 1H, Ar), 7.35
(d, J = 6.5 Hz, 1H, Ar), 7.38 (d, J = 6.5 Hz, 1H, Ar), 7.54 (m, 3H, Ar), 7.82 (d, J = 7.0 Hz, 1H, Ar), 8.11
(m, 3H, Ar), 9.79 (s, 1H, CH), 12.77 (s, 1H, NH), 12.86 (s, 1H, OH), 13.58 (s, 1H, NH). 13C-NMR: δ 111.6,
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115.9, 122.0, 123.2, 123.6, 126.1, 126.8, 127.8, 131.0, 132.1, 135.0, 136.2, 137.8, 145.7, 147.3, 151.8, 158.0,
161.3. MS m/z 331 (M + H)+. Anal. Calcd for C19H14N4O2: C, 69.08; H, 4.27; N, 16.96. Found: C, 69.14;
H, 4.29; N, 17.01.
(E)-N1-(Naphthalen-1-ylmethylene)-1H-benzo[d]imidazole-2-carbohydrazide (19). Yield 92%. Mp > 250 ˝C
(EtOH). IR: 3208, 3044, 1618, 1558 cm´1. 1H-NMR: δ 7.32 (m, 2H, Ar), 7.65 (m, 4H, Ar), 7.81 (m, 1H, Ar),
8.01–8.16 (m, 3H, Ar), 8.74 (m, 1H, Ar), 9.44 (s, 1H, CH), 12.54 (s, 1H, NH), 13.55 (s, 1H, NH). 13C-NMR:
115.0, 122.9, 123.1, 126.0, 126.2, 127.5, 128.4, 128.5, 130.2, 130.6, 130.7, 138.6, 143.3, 144.8, 155.6. ESI-MS




Human cervical carcinoma (HeLa), human T-lymphoblast (CEM) and mouse leukema (L1210)
cells were obtained from ATCC (Middlesex, UK). Human pancreatic carcinoma (Mia-Paca 2) cells were
kindly provided by Prof. Anna Karlsson (Karolinska Institute, Stockholm, Sweden). All cell lines were
grown in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Carlsbad, CA, USA), supplemented
with 10% fetal bovine serum (FBS, Gibco), 0.01M Hepes (Gibco) and 1 mM sodium pyruvate (Gibco) in
a humidified 5% CO2 incubator at 37 ˝C.
4.3.2. Cell Proliferation
Suspension (L1210 and CEM cells) were seeded in 96-well microtiter plates at 60,000 cells/well in
the presence of different concentrations of the compounds. The cells were allowed to proliferate for
48 h or 96 h, respectively and then counted in a Coulter counter. The 50% inhibitory concentration
(IC50) was defined as the compound concentration required to reduce cell proliferation by 50%. HeLa
and Mia-Paca2 cells were seeded in 96-well plates at 15,000 cells/well in the presence of different
concentrations of the compounds. After 4 days of incubation, the cells were trypsinized and counted
in a Coulter counter.
4.3.3. IC50 Determination
The compounds were dissolved in DMSO at 20 mM (stock solution) and kept in the refrigerator
until use. Then, compound dilutions were made in cell culture medium, and serial compound
concentrations were tested starting at 100 µM as the highest concentration. The DMSO concentration,
present in the highest compound concentration was 0.5% that is a concentration that did not
affect the tumor cell proliferation. The IC50 values were calculated using following formula:
C1 ´ [ 50 ´ N1%/N2% ´ N1% ] ˆ ( C1 ´ C2) wherein C1 is the compound concentration that inhibits
cell proliferation more than 50%; C2 is the compound concentration that inhibits cell proliferation less
than 50%; N1% represents the cell number (in percent of control in the absence of compound) obtained
in the presence of C1 and N2% represents the cell number (in percent of control in the absence of
compound) obtained in the presence of C2.
5. Conclusions
This study started with the aim to explore the possible antiproliferative properties of dualistic
molecules bearing a combination of the hydrazone and benzimidazole moieties. Based on compounds
3–19 the in vitro activity on murine leukemia (L1210), human T-lymphoblastic leukemia (CEM), human
cervix carcinoma (HeLa) and human pancreas carcinoma (Mia Paca-2) cells, we have observed that
the presence of a 2-hydroxyl group on the arylidene moiety favourably modulates antiproliferative
activity. In particular, hydrazones 10 and 16 inhibited the growth of all tested cell lines with low
(<10 µM) micromolar IC50 values. Predictions of the ADME properties for studied compounds showed
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that all hydrazones 3, 6–8, 10, 11, 13–16 might present good passive oral absorption. In conclusion
by combination of benzimidazole and hydrazone pharmacophores we obtained a new class of
N1-(4-arylidene)-1H-benzo[d]imidazole-2-carbohydrazides endowed with significant antiproliferative
activity as well as good potential absorption properties. These results further encourage us in
developing an enlarged synthetic study in order to highlight SAR in this interesting class of molecules.
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